Healthcare / Drug Manufacturers - Specialty & GenericBSE
$503.05
+2.95 (+0.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-41.7M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
63/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
12.8x
↓EV/EBITDA
5.2x
↓ROE
12.0%
↑Gross Margin
49.6%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.2%
FCF CAGR
—
FCF margin
-3.6%
FCF / Net income
-0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.15B · net income $241.6M · FCF $-41.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.15B | $1.15B | $821.0M | $778.9M | $732.2M |
| Net Income | $241.6M | $241.6M | $157.9M | $64.5M | $90.5M |
| EBITDA | $345.8M | $345.8M | $227.1M | $107.4M | $139.9M |
| EPS | 67.61 | 67.61 | 44.19 | 18.04 | 25.32 |
| Gross Margin | 49.6% | 49.6% | 56.5% | 36.8% | 41.8% |
| Operating Margin | 21.4% | 21.4% | 17.4% | 2.1% | 8.5% |
| Net Margin | 21.0% | 21.0% | 19.2% | 8.3% | 12.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | — | — | 0.04 |
| Cash Flow | |||||
| Free Cash Flow | $-41.7M | $-41.7M | $-64.6M | $107.2M | $5.4M |
| Returns | |||||
| ROE | 12.0% | 12.0% | 8.9% | 4.2% | 5.8% |
| Valuation | |||||
| P/E | 12.85 | 12.85 | — | — | — |
| EV/EBITDA | 5.20 | 5.20 | — | — | — |
| P/B | 0.89 | 0.89 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 40.1% | 40.1% | 5.4% | 6.4% | — |
| EPS Growth | 53.0% | 53.0% | 145.0% | -28.8% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-12.9%
EPS terminal req.
$44.64
Spread vs growth
65.9%
5Y implied EPS CAGR
-4.4%
EPS terminal req.
$54.01
Spread vs growth
57.4%
10Y implied EPS CAGR
2.6%
EPS terminal req.
$86.99
Spread vs growth
50.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-34.3%
Start / end P/E
17.4x → 7.4x
EPS bridge
44.19 → 67.61
Residual
-30.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.